IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells

Background: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their associa...

Full description

Bibliographic Details
Main Authors: Alessio Ugolini, Ilaria Grazia Zizzari, Fulvia Ceccarelli, Andrea Botticelli, Tania Colasanti, Lidia Strigari, Aurelia Rughetti, Hassan Rahimi, Fabrizio Conti, Guido Valesini, Paolo Marchetti, Marianna Nuti
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:EBioMedicine
Subjects:
NSCLC
IgM-rheumatoid factor
anti-PD-1 ICIs
Prognostic biomarker
Survival
CD137+ T-cells
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420304746

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420304746

Similar Items